.png){kind=icon}
.png){kind=icon}
Return
Nitrogen-containing FDA-approved drugs in 2025: synthesis; significance and therapeutic applications
.png){kind=icon}
OA
AI
J
S
G
S
V
DOI：10.1039/D6RA00737F.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Nitrogen-containing heterocycles (N-Hets) are among the most prevalent and versatile structural motifs in pharmaceuticals; serving as key scaffolds in over 85% of biologically active small molecules. Their structural diversity and functional versatility have made them integral components of both U.S. Food and Drug Administration (FDA) approved and investigational drug molecules; modulating biological activity across a range of molecular targets. In 2025; the FDA approved 26 small-molecule drugs featuring N-Het frameworks; spanning multiple therapeutic areas; including oncology; metabolic disorders; infectious diseases; and rare/orphan conditions. This review offers a comprehensive overview of these newly approved compounds; emphasizing their biological activity and synthetic approaches. Special attention is given to drug–target interactions; focusing on receptor binding and highlighting the important role of N-Hets in medicinal chemistry. By exploiting the intrinsic chemical properties of N-Hets and leveraging modern synthetic methodologies; these scaffolds continue to drive the discovery of therapeutically relevant molecules; highlighting their sustained significance in modern drug discovery.
Keywords:
Nitrogen-containing heterocycles
FDA-approved drugs
medicinal chemistry
drug discovery
therapeutic applications
Journal
R
IF:
0
Papers:
1.7K
Citations:
2
View more organizations